Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.D-Pharm has selected Hangzhou Tigermed Consulting (Hangzhou Tigermed) as the contract research organisation to manage the regulatory filings and conduct the clinical trials of DP-b99, in China.
Subscribe to our email newsletter
The agreement was signed together with Wanbang Biopharmaceuticals, as part of the D-Pharm – Wanbang co-development program for DP-b99 in China.
Discovered and developed by D-Pharm, DP-b99 is currently being tested in a pivotal Phase III multinational clinical study in ischemic stroke patients (study acronym MACSI).
D-Pharm CEO Alex Kozak said that considerable effort has gone into the selection of CRO, with the appropriate experience in regulatory filings and stroke trial management, to conduct and manage the studies in China according to the highest possible standards.
"Given the huge stroke burden in China, I view this agreement as a significant step that will enable us to broaden our DP-b99 clinical data package and hopefully bring our drug to the Chinese market as quickly as possible," Kozak said.